Comprehensive Characterization of Anti-CTLA4 Monoclonal Antibody by Liquid Chromatography High Resolution Mass Spectrometry
WU Gang, WANG Wen-bo, YU Chuan-fei, CUI Yong-fei, ZHANG Rong-jian, WANG Lan*
Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, Beijing 102629, China
Abstract：OBJECTIVE To establish a mass spectrometry method for the qualitative analysis of anti-CTLA4 monoclonal antibody and its N-linked glycosylation. METHODS The anti-CTLA4 monoclonal antibody was characterized by liquid-mass technique from the aspects of intact molecular weight, subunit molecular weight, amino acid sequence coverage, disulfide bond, N-linked glycosylation site and glycoform. RESULTS The molecular weight of anti-CTLA4 mAb (A2G0F/A2G0F) is 147 992; the deglycosylation molecular weight of anti-CTLA4 mAb is 145 103; the molecular weight of light chain is 23 450; the molecular weight of heavy chain (A2G0F) is 50 548; the heavy chain Fd segment has a molecular weight of 25 355 and the heavy chain sFc segment (A2G0F,1xK_Loss) has a molecular weight of 25 189. Peptide mapping was performed with Trypsin & Chymotrypsin, and the coverage of the amino acid sequence was 100%. The peptide containing the N-linked glycosylations site is EEQYNSTYR, and the N-glycosylation site is located at Asn298 of the heavy chains. Thirteen glycoform were characterized including A2G0F(59.8%), A2G1Fa(18.66%), A2G1Fb(7.28%), A2G2F(3.2%), M5(1.66%), A2S1G0F(1.17%), A1G0F (1.16%), A3G1F(0.95%), A2G0(0.94%), A2S2F(0.78%), A2S1G1F(0.67%), A3G0F(0.53%)and A1G1F(0.51%). CONCLUSION A method for qualitative and quantitative analysis of monoclonal antibody is established.
KAPLON H, REICHERT J M. Reichert, antibodies to watch in 2019 [J]. MABS,2019, 11(2):219-238.
[2]
CHAMES P, VAN R M, WEISS E, et al. Therapeuticantibodies:successes, limitations and hopes for the future [J]. Br J Pharmacol, 2009, 157(2):220-233.
[3]
WEINER G J. Building better monoclonal antibody-based therapeutics [J]. Nat Rev Cancer, 2015, 15(6):361-370.
[4]
KAPLON H, REICHERT J M. Antibodies to watch in 2018 [J]. MABS, 2018, 10(5):183-203.
[5]
LIU H, GAZA B G, FALDU D, et al. Heterogeneity of monoclonal antibodies[J]. J Pharm Sci, 2008, 97(7):2426-2447.
[6]
WANG W, SINGH S, ZENG D L, et al. Antibody structure, instability, and formulation[J]. J Pharm Sci, 2007, 96(1):1-26.
[7]
MUKHERJEE R, ADHIKARY L, KHEDKAR A, et al. Probingdeamidation in therapeutic immunoglobulin gamma (IgG1) by‘bottom-up′ mass spectrometry with electron transfer dissociation [J]. Rapid Commun Mass Spectrom, 2010, 24(7):879-884.
[8]
LADWIG P M, BARNIDGE D R, WILLRICH M A V. Mass spectrometry approaches for identification and quantitation of therapeutic monoclonal antibodies in the clinical laboratory [J]. Clin Vaccine Immunol, 2017, 24(5):545-516.
[9]
ZHANG Z, PAN H, CHEN X. Mass spectrometry for structural characterization of therapeutic antibodies[J]. Mass Spectrom Rev, 2009, 28(1):147-176.
[10]
ROGSTAD S, FAUSTINO A, RUTH A, et al. A retrospective evaluation of the use of mass spectrometry in FDA biologics license applications[J]. J Am Soc Mass Spectr, 2017, 28(5):786-794.
[11]
TAO L, DING Y X, LIU L, et al. Indentification of several kinds of post-translational modifications in recombinant protein pharmaceuticals using MS /MS[J]. Chin Pharm J(中国药学杂志),2015,50(19):1726-1730.
[12]
WANG W B, YU C F, ZHANG F, et al. Analysis of N-linked glycan profile of therapeutic antibodies by UPLC -Qda MSs[J]. Chin Pharm J(中国药学杂志),2018, 53 (3):223-227.
2020, Vol. 55 
